Colombia’s Supreme Court Affirms Compulsory License for HIV Drug, Strengthening Access
On May 11, 2026, the Court of Justice of the Andean Community, the highest judicial body for the Andean bloc, upheld Colombia’s decision to issue a compulsory license for the antiretroviral drug dolutegravir in 2024. The ruling confirms the legality of the government’s move to allow local manufacturers to produce a cheaper generic version, bypassing patents held by a multinational pharmaceutical consortium.
Compulsory licensing is a legal mechanism that permits a government to authorize the production of a patented medicine without the consent of the patent holder, typically invoked during public‑health emergencies or when drug prices are deemed unaffordable. Colombia has faced rising HIV prevalence and high treatment costs, prompting the Ministry of Health to act after negotiations with the patent owners stalled. The decision aligns with the 2001 Doha Declaration on TRIPS and public health, which encourages flexibilities for essential medicines.
Stat News reported that the court found the Ministry’s justification—ensuring affordable access for over 200,000 patients—to be “well‑grounded and consistent with regional trade agreements.” Conversely, Reuters noted that the pharmaceutical companies, led by GSK and Pfizer, argued the license would undermine incentives for research and development, but the court dismissed those claims as “non‑substantiative.” The ruling also cites precedent from Brazil’s 2007 HIV‑drug license, reinforcing a growing Latin‑American trend toward leveraging TRIPS flexibilities. The generic version is expected to cost roughly 60% less than the branded product, according to Colombia’s health ministry.
Health economists, such as Dr. Luis Ortega of Universidad de los Andes, view the verdict as a watershed for drug‑access policy across the region, stating, "It sends a strong signal that governments can prioritize public health over patent monopoly when prices become prohibitive." Advocacy groups like the Treatment Action Group welcomed the outcome, urging other nations to consider similar steps. However, pharmaceutical lobbyists warn that repeated use of compulsory licensing could erode global investment in new HIV therapies.
The decision opens a window for Colombia to negotiate further price reductions with other drug manufacturers and may prompt neighboring countries to revisit their own patent strategies. The Ministry plans to issue the manufacturing contract to a domestic firm by July 2026, with rollout of the generic drug slated for the fourth quarter. International observers will monitor whether the move spurs additional legal challenges or encourages broader adoption of compulsory licenses in the Andean Community.